You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A Self-Replicating RNA Vaccine Against HIV-1 Delivered Using A Nanoparticle Adjuvant
SBC: PAI LIFE SCIENCES INC Topic: NIAIDAn effective vaccine against HIV offers the best chance to stop the global epidemic but remains elusive to dateResearch has primarily focused on subunit monomerice ggpor gpor trimeric antigensthe former approachoften adjuvanted with alumhas failed in clinical trialsNative like trimers mimic the Env spike but are still poorly immunogenic and require elaborate adjuvant screening efforts to potentiat ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Development of a Prophylactic Onchocerciasis Vaccine
SBC: PAI LIFE SCIENCES INC Topic: NIAIDHumanriver blindnessis caused by a filarial parasite and is a serious neglected tropical disease contributing to blindnessskin diseaseand chronic disability in the developing worldEstimates from the Global Burden of Disease Studyindicate thatmillion cases of onchocerciasisleading tomillion cases of vision impairmentoccur worldwide every yearThe goal of this project is to develop a safe and effecti ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Development of Membrane Anchored Cytokines as Novel Vaccine Adjuvants for the Elderly
SBC: METACLIPSE THERAPEUTICS CORP Topic: NIAIDlnterleukinILand granulocyte macrophage colony stimulating factorGM CSFare endogenous immune activatorsEarlier studies using soluble ILand GM CSF as vaccine adjuvants were unsuccessful due to toxicity or suboptimal responseWe developed versions of ILand GM CSF with a glycosylated phosphatidylinositolGPIanchor added at the carboxyl terminusallowing incorporation into lipid bilayers such as in influ ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Creating Antibodies to Enable the Study of Mycobacterium Tuberculosis Infections in Guinea Pigs
SBC: GLYCOSCIENTIFIC, L.L.C. Topic: NIAIDTuberculosis is a persistent infectious disease that threatens the health of people and numerous mammalian species throughout the worldMonitoring of Mycobacterium tuberculosisMtbinfections in animal models has often relied on host mortalitybacterial loadsand qualitative assessment of pathology at necropsyThese are blunt toolslargely unrelated to the markers used for diagnosis and epidemiological s ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Rational Development of a Combination Nanoparticle Adjuvant for Influenza
SBC: HDT BIO CORP Topic: NIAIDSignificanceHighly pathogenic avian H Ninfluenzawhich has killedpeople sinceis poised to cause a pandemic in a worldwide population that has no pre existing immunityCurrent Hvaccines are insufficiently immunogenic without the addition of adjuvantsbut responses to these adjuvanted vaccines are not durable and may not be protective against newly emergent viral strainsProposed solutionWe have develop ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Person-Centered Planning ToolKit: Development of an Application to Improve Workforce Participation for Individuals with Cognitive Disabilities Through Team Collaboration and Employment Discovery
SBC: ASSISTECH SYSTEMS LLC Topic: naThis project evaluates the usability and feasibility of a Person-Centered Planning Toolkit to address the need for increased opportunities for competitive integrated employment for individuals with cognitive disabilities. The Toolkit enhances implementation of person-centered planning (PCP), often limited by lack of follow-through on action items, and a lack of tools to match career preferences to ...
SBIR Phase II 2019 Department of Health and Human ServicesAdministration for Community Living -
A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects
SBC: Syntrix Biosystems, Inc. Topic: NIDAFromthe utilization of the Schedule II opioids codeineOxyContin and fentanyl declined significantlydown aboutfor all three drugsIn sharp contrastthe use of tramadola Schedule IV controlled substanceincreasedSchedule IV substances have low potential for abuse and harm relative to Schedule II substancesand the fortuitous trend to tramadol has reduced the use of the relatively unsafe Schedule II opio ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Immuno Oncology Product for Multiple Myeloma: g-NK Cellular Therapy to Optimize Monoclonal Antibody Efficacy in Treating Multiple
SBC: Indapta Therapeutic Topic: 102Project Summary Abstract Multiple myeloma is the second most common hematologic malignancy in the USwith aboutnew cases in the US each yearMost patients with MM relapse and eventually become unresponsive to treatmentAlthough multiple new therapies for MM have come on the markettheir promise is limited by concerns about toxicity and low efficacyand MM remains incurableThereforethere is an urgentdem ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Novel sanitizer/disinfectants against viral infections with long-lasting effect
SBC: CAMELLIX, LLC Topic: NIAIDAbstractNorovirus is the most common cause of acute gastroenteritis in the United States, associated annually with 19-21 million illnesses, 56,000-71,000 hospitalizations and 570-800 deaths (US CDC, Overview about Norovirus). Norovirus is one of the nonenveloped viruses that are resistant to alcohol sanitization. According to US CDC Guidelines for the Prevention and Control of Norovirus Gastroente ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Translational development of specialized NK cells for cancer immunotherapy
SBC: Indapta Therapeutic Topic: 102Project Summary Abstract The annual incidence of head and neck cancers worldwide is more thancases with arounddeaths each yearand it is estimated that inthere will benew cases of non Hodgkin lymphoma with an estimateddeaths this yearIn this proposalwe describe a strategy to use a novel subset of natural killer cellsg NK cellsallogeneically for cancer therapyWe hypothesize that expansion and adopti ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health